Sign in

INBP on OTC

INTEGRATED BIOPHARMA INC

INTEGRATED BIOPHARMA INC is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Hillside, New Jersey.1 Its shares trade on OTC under the symbol INBP.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$43.9MRevenue, fiscal 20262
-$2.8MNet income, fiscal 20262

Compare with Xilio Therapeutics, Inc., CUMBERLAND PHARMACEUTICALS INC or Aquestive Therapeutics, Inc., or pick any stock.

  • TickerINBP on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHillside, New Jersey1
  • Incorporated inDE3
  • Business address225 Long Avenue, Building 15, Hillside, Nj 072053
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

1.8%Gross margin2
-6.2%Operating margin2
-6.5%Net margin2
-19.3%Revenue growth, 20262
-16.1%Return on equity2
$895.0KFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Contract Manufacturing brought in 97% of the revenue INTEGRATED BIOPHARMA INC broke down this way in fiscal 2026.

  1. Contract Manufacturing$42.4M297%down 18% from 2025
  2. Other Nutraceutical Business$1.5M23%down 44% from 2025
Business segments by year
Business segments20252026
Contract Manufacturing$51.7M$42.4M
Other Nutraceutical Business$2.7M$1.5M

Regions

United States brought in 80% of the revenue INTEGRATED BIOPHARMA INC broke down this way in fiscal 2026.

  1. United States$35.2M280%down 19% from 2025
  2. Outside the United States$8.6M220%down 19% from 2025
Regions by year
Regions20252026
United States$43.6M$35.2M
Outside the United States$10.7M$8.6M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue92¢$43.1M
  • Selling, general and admin7¢$3.5M
  • Interest0¢$12.0K
  • Income tax1¢$279.0K

Out of $43.9M in revenue.2 The company lost money this year.

Where each dollar of operating cash went, fiscal 2026

  • Capital spending28¢$346.0K
  • Kept or used elsewhere72¢$895.0K

Out of $1.2M of cash from operations.2

Financial statements

Revenue56789102$43.9M in 2026−12% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $50.0M$50.0M20192020: $52.8M$52.8M2020+6%2021: $63.6M$63.6M2021+20%2022: $56.2M$56.2M2022−12%2023: $50.7M$50.7M2023−10%2024: $50.3M$50.3M2024−1%2025: $54.4M$54.4M2025+8%2026: $43.9M$43.9M2026−19%
Gross profit56789102$800.0K in 2026−87% since 2019
0$2.5M$5.0M$7.5M$10.0M2019: $6.2M$6.2M20192020: $6.7M$6.7M2020+8%2021: $9.5M$9.5M2021+41%2022: $6.6M$6.6M2022−31%2023: $4.1M$4.1M2023−38%2024: $3.9M$3.9M2024−4%2025: $5.6M$5.6M2025+43%2026: $800.0K$800.0K2026−86%
Operating income56789102-$2.7M in 2026
-$5.0M-$2.5M0$2.5M$5.0M$7.5M2019: $2.7M$2.7M20192020: $3.3M$3.3M2020+21%2021: $5.8M$5.8M2021+77%2022: $2.7M$2.7M2022−53%2023: $120.0K$120.0K2023−96%2024: $251.0K$251.0K2024+109%2025: $2.0M$2.0M2025+705%2026: -$2.7M-$2.7M2026
Net income56789102-$2.8M in 2026
-$5.0M0$5.0M$10.0M2019: $1.7M$1.7M20192020: $4.1M$4.1M2020+143%2021: $8.0M$8.0M2021+95%2022: $3.8M$3.8M2022−52%2023: -$34.0K-$34.0K20232024: $112.0K$112.0K20242025: $808.0K$808.0K2025+621%2026: -$2.8M-$2.8M2026

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2026-06-302025-06-30
Sales, net$43.9M$54.4M
Cost of sales$43.1M$48.8M
Gross profit$800.0K$5.6M
Selling and administrative expenses$3.5M$3.5M
Operating (loss) income-$2.7M$2.0M
Interest income, net$154.0K$39.0K
Other income (expense), net-$12.0K$3.0K
Total other income, net$142.0K$42.0K
(Loss) income before income taxes-$2.6M$2.1M
Income tax expense, net$279.0K$1.3M
Net (loss) income-$2.8M$808.0K
Basic net (loss) income per common share (in dollars per share)-$0.09$0.03
Diluted net (loss) income per common share (in dollars per share)-$0.09$0.03
Weighted average common shares outstanding - basic (in shares)31.1M shares30.3M shares
Add: Equivalent shares outstanding - stock options (in shares)0 shares872.7K shares
Weighted average common shares outstanding - diluted (in shares)31.1M shares31.2M shares

Compare INTEGRATED BIOPHARMA INC with another company

Corporate structure

INTEGRATED BIOPHARMA INC sits at the top of its group. 8 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of INTEGRATED BIOPHARMA INC

  • Carl Desantis Filed SCHEDULE 13D/A on INTEGRATED BIOPHARMA INC, latest Apr 17, 2026
  • Damon Desantis Filed SCHEDULE 13D on INTEGRATED BIOPHARMA INC, latest Apr 17, 2026
  • INTEGRATED BIOPHARMA INC Hillside, New Jersey
    • AgroLabs, Inc. Subsidiary · New Jersey, United States
    • IHT Health Products, Inc. Subsidiary · Delaware, United States
    • IHT Properties, Inc. Subsidiary · Delaware, United States
    • InB:Paxis Pharmaceuticals, Inc. (f/k/a Paxis Pharmaceuticals, Inc.) - inactive Subsidiary · Delaware, United States
    • Manhattan Drug Company, Inc. Subsidiary · New Jersey, United States
    • MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) Subsidiary · New Jersey, United States
    • Vitamin Factory, Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What INTEGRATED BIOPHARMA INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$10.2M2 Jun 30, 2026$9.9M2 Jun 30, 2025+2.7%
Accumulated depreciation$8.4M2 Jun 30, 2026$8.2M2 Jun 30, 2025+2.9%
Property and equipment, net$1.8M2 Jun 30, 2026$1.7M2 Jun 30, 2025+1.8%
Finance-lease assets$144.0K2 Jun 30, 2026$171.0K2 Jun 30, 2025−15.8%
Operating-lease assets (leased space)$2.9M2 Jun 30, 2026$855.0K2 Jun 30, 2025+242.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.5M2 Jun 30, 2026$3.6M2 Jun 30, 2025+23.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$9.1M2 Jun 30, 2026$9.4M2 Jun 30, 2025−2.3%
Raw materials$6.1M2 Jun 30, 2026$5.7M2 Jun 30, 2025+6.5%
Work in process$1.9M2 Jun 30, 2026$2.7M2 Jun 30, 2025−30.5%
Finished goods$1.1M2 Jun 30, 2026$901.0K2 Jun 30, 2025+26.9%

Properties, in its own words

Warehouse and office facilities are leased from Vitamin Realty, which is controlled with 41% ownership by each of the Company’s Co-Chief Executive Officers and directors of the Company and 18% by their mother, a major stockholder of the Company. On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment to the lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in Hillside, New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026.

On July 15, 2022, MDC entered into a third amendment to the lease (the “Third Lease Amendment”) with Vitamin Realty, increasing its rentable square footage to 116,175. This Third Lease Amendment provides for minimum annual rental payments of $842, plus increases in real estate taxes and the building operating expenses allocation percentage and was effective as of July 1, 2022. On February 17, 2026, MDC entered into a fourth amendment of the lease (the “Fourth Lease Amendment”). The Fourth Amendment, decreases the rentable square footage to 110,095, provides for minimum annual rental payments of $1,101 and extends the expiration date to January 31, 2029.

The rest of Item 2

We also own a 40,000 square foot manufacturing facility in Hillside, New Jersey. The space is utilized for MDC’s tablet and capsule manufacturing operations.

In November 2022, MDC Warehousing and Distribution, Inc. entered into a lease agreement for 12,500 square feet of warehouse space in Elizabeth, New Jersey. This lease provides for minimum annual rent payments starting at $134 in year one, with a gradual increase to $150 by year 5. The lease expiration date is November 30, 2027.

Item 2 of the 10-K filed Sep 25, 2026.13

Leadership

Who has led INTEGRATED BIOPHARMA INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. E. Gerald Kay2006–2018
  2. Jeffrey R. Leach2008
  3. Christina Kay2019–now
  4. Kay Riva2019–now

Chair

  1. E. Gerald Kay2019–2023

President

  1. Christina Kay2006
  2. Jeffrey R. Leach2008
  3. E. Gerald Kay2009–2023

Chief financial officer

  1. Dina Masi2006–now
2010201520202025
Board members and other officers (17)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • AgroLabs, Inc. New Jersey4
  • IHT Health Products, Inc. Delaware4
  • IHT Properties, Inc. Delaware4
  • InB:Paxis Pharmaceuticals, Inc. (f/k/a Paxis Pharmaceuticals, Inc.) - inactive Delaware4
  • MDC Warehousing and Distribution, Inc. (f/k/a The Organic Beverage Company) New Jersey4
  • Manhattan Drug Company, Inc. New Jersey4
  • Vitamin Factory, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • INTEGRATED HEALTH TECHNOLOGIES INCSep 12, 2002 to Apr 16, 20033
  • CHEM INTERNATIONAL INCDec 9, 1996 to May 14, 20023

Timeline

  1. Sep 25, 20268-K Results of operations35
  2. Aug 20, 20268-K Other events36
  3. Jul 2, 20268-K Entered a material agreement; Ended a material agreement37
  4. May 8, 20268-K Results of operations38
  5. Apr 15, 20268-K Other events39
  6. Feb 18, 20268-K Entered a material agreement40
  7. Feb 11, 20268-K Results of operations41
  8. Dec 1, 20258-K Shareholder vote42
  9. Nov 10, 20258-K Results of operations43
  10. Sep 23, 20258-K Results of operations44
  11. May 14, 20258-K Results of operations45
  12. Apr 24, 20258-K Change of auditor46
  13. May 29, 2019New chief executive Kay Riva becomes CEO15
  14. May 29, 2019New chief executive Christina Kay becomes CEO14
  15. Nov 17, 2008New chief executive Jeffrey R. Leach becomes CEO16
  16. Dec 4, 2006New chief executive E. Gerald Kay becomes CEO17

Calendar

When it reported results

  1. Sep 25, 2026Reported quarterly or annual results35
  2. May 8, 2026Reported quarterly or annual results38
  3. Feb 11, 2026Reported quarterly or annual results41
  4. Nov 10, 2025Reported quarterly or annual results43
  5. Sep 23, 2025Reported quarterly or annual results44
  6. May 14, 2025Reported quarterly or annual results45
  7. Feb 13, 2025Reported quarterly or annual results47
  8. Nov 14, 2024Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

134 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 38 major events, 67 insider forms, 4 large holders, 5 other. The latest 20:

  1. Sep 25, 20268-K EDGAR
  2. Sep 25, 202610-K EDGAR
  3. Aug 20, 20268-K EDGAR
  4. Jul 2, 20268-K FORM 8-K PNC FIRST AMENDMENT EDGAR
  5. Jun 25, 20264 PRIMARY DOCUMENT EDGAR
  6. Jun 25, 20264 PRIMARY DOCUMENT EDGAR
  7. Jun 25, 20264 PRIMARY DOCUMENT EDGAR
  8. Jun 25, 20264/A PRIMARY DOCUMENT EDGAR
  9. Jun 25, 20264 PRIMARY DOCUMENT EDGAR
  10. May 8, 20268-K EDGAR
  11. May 8, 202610-Q EDGAR
  12. Apr 17, 20264/A PRIMARY DOCUMENT EDGAR
  13. Apr 17, 20264 PRIMARY DOCUMENT EDGAR
  14. Apr 17, 2026SCHEDULE 13D EDGAR
  15. Apr 17, 20264 PRIMARY DOCUMENT EDGAR
  16. Apr 17, 2026SCHEDULE 13D/A EDGAR
  17. Apr 17, 20264 PRIMARY DOCUMENT EDGAR
  18. Apr 15, 20268-K EDGAR
  19. Mar 26, 20264 PRIMARY DOCUMENT EDGAR
  20. Mar 25, 20264 PRIMARY DOCUMENT EDGAR

The 134 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Dina Masi$280.0K$334.6K51
2025Co-Chief Executive Officer$268.0K$325.0K51
2024Chief Financial Officer and$263.9K$343.7K51
2024Co-Chief Executive Officer$268.0K$331.3K51

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.6M 2020–2020
Money received by yearMoney received by year, 2020–2020: $1.6M in all. PPP loans $1.6M.$0$500K$1M$1.5M$2M2020 · PPP loans: $1.6M2020
Figures by year
YearPPP loansTotal
2020$1.6M$1.6M

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA52. Matched to this company by name and state.

  1. Apr 27, 2020$1.6M PPP loan (first draw) from PNC Bank, National Association52To INTEGRATED BIOPHARMA INC, Hillside NJ; $1.7M forgiven Jun 29, 2021

SEC filer profile

How INTEGRATED BIOPHARMA INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARINTEGRATED BIOPHARMA INC1
  • CIK0001016504
  • Employer ID (EIN)22-240747513
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company13
  • Incorporated inDelaware13
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address225 Long Avenue, Building 15, Hillside, NJ 072051
  • Phone97392608161
  • Shares outstanding31,059,610 shares as of Sep 23, 202613
  • Public float$3.4M as of Dec 31, 202513
  • AuditorCBIZ CPAs P.C., Morristown, New Jersey PCAOB ID 199; no auditor attestation of internal control over financial reporting13
  • On EDGAR sinceNov 21, 19961
  • Filings556 in all: 8-K (150), 4 (120), 10-Q (64), DEF 14A (27), 10QSB (26), 10-K (22), 5 (16), NT 10-Q (14)1
    All 46 form types

    3 (11), SC 13D (9), 10KSB (8), 4/A (6), 8-K/A (6), UPLOAD (6), NT 10-K (5), PRER14C (5), S-3/A (5), DEF 14C (4), S-3 (4), S-8 (4), 10-Q/A (3), DEFA14A (3), DEFR14A (3), PRE 14C (3), REGDEX (3), 25 (2), 8-A12B (2), ARS (2), CORRESP (2), EFFECT (2), SC 13D/A (2), SC 13G (2), SC 13G/A (2), 10-K/A (1), 10KSB/A (1), 10QSB/A (1), 424B3 (1), 8-A12G (1), 8-A12G/A (1), CERTAMX (1), CERTNAS (1), D (1), N-30D (1), RW (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Sep 25, 2026
    Quarterly report (10-Q) May 8, 2026
    Proxy statement (DEF 14A) Oct 28, 2025
    Latest 8-K (8-K) Sep 25, 2026

Risk factors and legal proceedings

The risks INTEGRATED BIOPHARMA INC names in Item 1A of its 10-K filed Sep 25, 2026: 21 risks under these headings, as written.13

  • Please carefully consider the following risk factors which could materially adversely affect our business, financial condition, operating results and cash flows. The risk factors described below are not the only ones we face. Risks and uncertainties not known to us currently, or that we currently deem immaterial, also may materially adversely affect our business, financial condition, operating results and cash flows.
  • Our revenue could decline significantly if we lose one or more of our most significant customers, which could have a significant adverse impact on us.
  • Supply chain disruptions resulting from geopolitical events could have an impact on our financial results and ability to timely ship products to our customers.
  • Complying with new and existing government regulation, both in the U.S. and abroad, could increase our costs significantly and adversely affect our financial results.
  • We may be exposed to or the target of legal proceedings initiated by regulators or third parties either in the United States or abroad which could increase our costs and adversely affect our reputation, revenues and operating income.
  • We depend on our senior management, the loss of whom would have an adverse effect on us.
  • We must continually maintain, protect, and upgrade our information-technology systems, including protecting against internal and external cyber-security threats, data breaches and emerging AI-driven attacks. Any such breach or system failure could result in significant business disruption, reputational harm and regulatory exposure.
  • Climate change and natural disasters may affect our business.
  • There is no assurance that we will remain quoted or listed on an active trading market.
  • We have entered into several transactions with entities controlled by some of our officers and directors, which could pose a conflict of interest.
  • Our Executive Officers and Directors have majority voting power and may take actions that may not be in the best interest of other stockholders, but in their own interest.
  • We have a staggered Board of Directors, which could impede an attempt to acquire the Company or remove our management.
The other 9 risks
  • Our product liability insurance may be insufficient to cover possible claims against us.
  • We may not be able to obtain raw materials used in certain of our manufactured products.
  • Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance.
  • We may incur significant professional service fees and other control costs that impact our financial condition.
  • If we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.
  • We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.
  • A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future.
  • Investors’ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.
  • Inflation and Tightened Labor Markets.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

The opening of Item 3, Legal Proceedings.13

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52